OPL-0401 Dose 1

Phase 2Small molecule

UUnknown Sponsor

OPL-0401 Dose 1 is one of 27 small molecule programs targeting Diabetic Retinopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic RetinopathyActive, not recruiting

Diabetic RetinopathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Diabetic Retinopathy

#DrugCompanyPhaseTrials

Precose

Bayer

Approved

1 2

Avapro

Sanofi

Approved

1 3

Farxiga

Tricor

3 5

EGRIFTA WR

TTheratechnologies

Approved

1 6

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 7

Decadron

AAspen Global Incorporated

Glucophage

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lodosyn

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Retinopathy1 trial

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

Active, not recruiting·UUnknown Sponsor·Phase 2·NCT05393284·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OPL-0401 Dose 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OPL-0401 Dose 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OPL-0401 Dose 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUnknown Sponsor

OPL-0401 Dose 1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Retinopathy1 trial

References

Drug Info

Quick Facts

Related News